Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04610671 · ClinicalTrials.gov registry record · Phase 1
Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT04610671 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 21 participants.
The verdict
NCT04610671, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Investigators will evaluate the safety and efficacy of combination neoadjuvant therapy using intravesical CG0070 and IV Nivolumab in cisplatin ineligible patients with Muscle Invasive Bladder Cancer (MIBC).
Interventions
- DRUG Nivolumab
- DRUG CG0070
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-10-26 |
| Est. Completion | 2024-07-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04610671
The ClinicalTrials.gov registry entry for NCT04610671 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT04610671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04610671 about?
NCT04610671 is a clinical study titled "Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC". Investigators will evaluate the safety and efficacy of combination neoadjuvant therapy using intravesical CG0070 and IV Nivolumab in cisplatin ineligible patients with Muscle Invasive Bladder Cancer (MIBC).
What is the current status of trial NCT04610671?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2020-10-26. Estimated completion is 2024-07-25.
What interventions are being tested in trial NCT04610671?
The interventions under investigation include: Nivolumab (DRUG), CG0070 (DRUG).
Who is sponsoring clinical trial NCT04610671?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.